#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	1336	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2407	163.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1820	1820	T	192	T	168	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	1336	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2407	163.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1554	1554	C	171	C	142	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2114	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3842	164.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1760	1760	A	194	A	160	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2114	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3842	164.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2394	2394	C	186	C	157	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2114	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3842	164.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2468	2468	A	196	A	161	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2114	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3842	164.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3020	3020	C	176	C	141	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	142	folP	855	855	100.0	folP.l15.c4.ctg.1	1639	25.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1163	1165	AGC	40;40;40	A;G;C	30;30;29	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	388	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3670	31.4	1	SNP	p	S91F	1	.	.	271	273	TTC	655	657	TTC	43;43;43	T;T;C	36;35;34	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	388	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3670	31.4	1	SNP	p	G95N	0	.	.	283	285	GGC	667	669	GGC	42;41;41	G;G;C	34;34;32	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	388	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3670	31.4	1	SNP	p	D95G	1	.	.	283	285	GGC	667	669	GGC	42;41;41	G;G;C	34;34;32	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	152	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1621	28.1	1	SNP	p	G45D	0	.	.	133	135	GGC	564	566	GGC	38;38;38	G;G;C	32;32;32	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	122	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1270	28.6	0	.	n	.	0	A197.	DEL	197	197	A	743	743	A	38	A	31	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	376	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3344	33.6	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1607	1609	GTC	28;28;29	G;T;C	25;26;26	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	376	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3344	33.6	1	SNP	p	D86N	0	.	.	256	258	GAC	713	715	GAC	53;53;53	G;A;C	39;39;39	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	376	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3344	33.6	1	SNP	p	R87W	0	.	.	259	261	CGT	716	718	CGT	53;52;52	C;G;T	39;38;37	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	376	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3344	33.6	1	SNP	p	S87R	1	.	.	259	261	CGT	716	718	CGT	53;52;52	C;G;T	39;38;37	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	376	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3344	33.6	1	SNP	p	R87I	0	.	.	259	261	CGT	716	718	CGT	53;52;52	C;G;T	39;38;37	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	376	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3344	33.6	1	SNP	p	S88P	0	.	.	262	264	TCC	719	721	TCC	52;52;52	T;C;C	37;38;38	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	318	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2991	31.6	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1540	1542	TGC	38;37;37	T;G;C	30;29;30	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	318	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2991	31.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1750	1752	GGC	34;34;34	G;G;C	26;27;28	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	286	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	30.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1458	1460	GCA	42;41;41	G;C;A,C	33;35;35,2	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	286	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	30.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1461	1463	ATC	41;42;42	A;T;C	36;32;38	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	286	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	30.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1473	1475	GTG	40;40;40	G;T,G;G	34;32,1;35	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	286	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	30.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1473	1475	GTG	40;40;40	G;T,G;G	34;32,1;35	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	286	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	30.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1977	1979	ACC	24;24;24	A;C;C	21;22;22	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	286	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	30.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2031	2033	GCG	21;21;22	G;C;G	18;17;18	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	286	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	30.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2031	2033	GCG	21;21;22	G;C;G	18;17;18	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	286	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	30.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2154	2156	GGC	18;20;20	G;G;C	15;17;17	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	286	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	30.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2163	2165	GGC	21;21;21	G;G;C	18;18;16	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	286	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2761	30.9	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2181	2183	TCG	24;24;24	T;C;G	20;21;20	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	404	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3421	35.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1747	1749	CCG	36;36;36	C;C,A;G,C	26;26,1;25,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	202	porA	1146	1146	99.56	porA.l15.c4.ctg.1	2052	29.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	702	702	C	30	C	24	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1958	49.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	636	638	GAA	66;66;66	G;A;A	57;59;59	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1958	49.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	924	926	GAT	63;63;63	G;A,G;T	48;50,1;50	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1958	49.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1047	1049	TCA	67;67;67	T,C;C;A	51,1;53;53	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1958	49.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1176	1178	GTC	69;68;69	G;T;C	60;61;62	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1958	49.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1506	1508	GCA	62;62;61	G;C,A;A	55;56,1;55	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1958	49.7	1	SNP	p	G120K	1	.	.	358	360	AAG	882	884	AAG	62;62;62	A,C;A;G	50,1;53;53	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1958	49.7	1	SNP	p	D121N	0	.	.	361	363	GAC	885	887	GAC	61;61;59	G;A;C	50;50;48	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	326	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1958	49.7	1	SNP	p	A121D	1	.	.	361	363	GAC	885	887	GAC	61;61;59	G;A;C	50;50;48	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	862	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5439	47.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2315	2317	AAT	53;53;55	A;A;T	43;44;45	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	150	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1247	36.1	1	SNP	p	V57M	1	.	.	169	171	ATG	618	620	ATG	67;66;65	A;T;G	54;55;55	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
